In a significant development at the ASCO 2025 Annual Meeting, AVEO Oncology, a subsidiary of LG Chem Life SciencesUSA, Inc., presented three posters highlighting their commitment to advancing oncology treatments. AVEO, known for its focus on delivering innovative medicines for cancer patients, currently offers FOTIVDA®(tivozanib) for advanced renal cell carcinoma treatment in the U.S. The company, in collaboration with strategic partners, is exploring new targeted combinations for RCC treatment using FOTIVDA. Additionally, AVEO is working on investigational programs targeting areas with high unmet medical needs such as HPV-negative refractory head and neck squamous cell carcinoma and cancer cachexia. Acquired by LG Chem Life SciencesUSA, Inc. in January 2023, AVEO continues its operations under the name AVEO Oncology. Stay tuned for more updates on their groundbreaking research in the field of oncology.
Read more about this — here
